BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38602755)

  • 21. Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells.
    Chen M; Feuerstein MA; Levina E; Baghel PS; Carkner RD; Tanner MJ; Shtutman M; Vacherot F; Terry S; de la Taille A; Buttyan R
    Mol Cancer; 2010 Apr; 9():89. PubMed ID: 20420697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
    Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
    Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53.
    Nesslinger NJ; Shi XB; deVere White RW
    Cancer Res; 2003 May; 63(9):2228-33. PubMed ID: 12727844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
    Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
    Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer.
    Zhang Z; Hou X; Shao C; Li J; Cheng JX; Kuang S; Ahmad N; Ratliff T; Liu X
    Cancer Res; 2014 Nov; 74(22):6635-47. PubMed ID: 25252916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate fibroblasts enhance androgen receptor splice variant 7 expression in prostate cancer cells.
    Sasaki T; Yoshikawa Y; Kageyama T; Sugino Y; Kato M; Masui S; Nishikawa K; Inoue T
    Prostate; 2023 Mar; 83(4):364-375. PubMed ID: 36479717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of small molecules modulating androgen receptor (SARMs) in human prostate cancer models.
    Tesei A; Leonetti C; Di Donato M; Gabucci E; Porru M; Varchi G; Guerrini A; Amadori D; Arienti C; Pignatta S; Paganelli G; Caraglia M; Castoria G; Zoli W
    PLoS One; 2013; 8(5):e62657. PubMed ID: 23667504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
    Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lncap-AI prostate cancer cell line establishment by Flutamide and androgen-free environment to promote cell adherent.
    Wang H; Wei X; Zhang D; Li W; Hu Y
    BMC Mol Cell Biol; 2022 Nov; 23(1):51. PubMed ID: 36443669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional roles of miR-625-5p and miR-874-3p in the progression of castration resistant prostate cancer.
    Aktan Ç; Çal Ç; Kaymaz B; Selvi Günel N; Kıpçak S; Özel B; Gündüz C; Şahin Küçükaslan A; Aygüneş Jafari D; Kosova B
    Life Sci; 2022 Jul; 301():120603. PubMed ID: 35508255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.
    Huang KC; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
    Cancer Biol Ther; 2014 Sep; 15(9):1120-8. PubMed ID: 24972028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
    Waltering KK; Helenius MA; Sahu B; Manni V; Linja MJ; Jänne OA; Visakorpi T
    Cancer Res; 2009 Oct; 69(20):8141-9. PubMed ID: 19808968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
    Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
    Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen receptor transcriptional activity is required for heregulin-1β-mediated nuclear localization of the HER3/ErbB3 receptor tyrosine kinase.
    Jathal MK; Siddiqui S; Vasilatis DM; Durbin Johnson BP; Drake C; Mooso BA; D'Abronzo LS; Batra N; Mudryj M; Ghosh PM
    J Biol Chem; 2023 Aug; 299(8):104973. PubMed ID: 37380074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.
    Mizokami A; Gotoh A; Yamada H; Keller ET; Matsumoto T
    J Urol; 2000 Sep; 164(3 Pt 1):800-5. PubMed ID: 10953159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
    Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH
    Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression.
    Lin DL; Whitney MC; Yao Z; Keller ET
    Clin Cancer Res; 2001 Jun; 7(6):1773-81. PubMed ID: 11410519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
    Nakayama H; Sekine Y; Oka D; Miyazawa Y; Arai S; Koike H; Matsui H; Shibata Y; Suzuki K
    Prostate; 2022 Feb; 82(3):314-322. PubMed ID: 34843630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.